Total treatment with tailored radiation for advanced rectal cancer
Part of Cancer, Digestive system clinical trials.
This study tests a “total neoadjuvant” approach—chemotherapy first, then radiation—using adaptive (tailored) radiation planning for people with locally advanced rectal cancer. It may help improve tumor control while adjusting the radiation based on how your cancer and anatomy respond.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have locally advanced rectal cancer with specific high-risk features (like T4a, threatened/close margins, certain lymph node involvement, or blood-vessel involvement).
- You have not had any prior treatment for rectal cancer.
- You have not had radiation to the same area before (for example, radiation for the prostate).
- You can do MRI scans (no MRI safety issues or metal/conditions that prevent MRI).
- Your overall health score is ECOG 0 or 1 (you are able to function fairly well).
- You cannot be pregnant, and you must be willing and able to sign consent; you also must be able to take the study drugs (5-FU, capecitabine, and oxaliplatin).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a full course of chemotherapy and radiation before any surgery (called total neoadjuvant therapy) can help you avoid surgery and preserve your rectum. It is for people with a specific early stage of rectal cancer that has not spread.
This Phase 2 study tests a “total neoadjuvant” approach, meaning you receive cancer treatment before surgery, to improve safety and effectiveness for rectal cancer. It may help by shrinking the tumor and planning a more effective operation, while researchers carefully track side effects.
This trial tests whether radiation therapy can be adjusted each session using MRI images to better target rectal cancer while sparing healthy tissue. It's for patients with stage II or III rectal cancer that hasn't spread to other parts of the body.
This trial tests a short course of radiation given before chemotherapy for people with locally advanced rectal cancer (cancer that has grown into nearby tissue and/or nearby lymph nodes but can still be removed). It may help shrink the tumor and make treatment more effective while assessing how well this approach works.
This study tests a new approach: using short-course radiation followed by a combination of chemotherapy (called TNT) before surgery for advanced rectal cancer that hasn't spread. The goal is to shrink the tumor and possibly avoid permanent colostomy.
This trial tests a shorter course of radiation combined with chemotherapy and immunotherapy before surgery for high-risk rectal cancer. The goal is to see if this combination shrinks the tumor more effectively and improves outcomes.
Hear when a new Rectal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.